Novo Nordisk partners with OpenAI to accelerate drug discovery and obesity treatment development
10 Sources
[1]
Novo Taps OpenAI to Speed Development of New Obesity Drugs
Novo Nordisk A/S will integrate OpenAI's artificial intelligence across the company to accelerate drug development. The Danish drugmaker didn't disclose financial terms of the partnership announced Tuesday, which adds to Novo's existing AI efforts that include a research-focused dealBloomberg
[2]
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab, which has fallen behind Eli Lilly (LLY.N), opens new tab in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business, from
[3]
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People walk past a sign for Novo Nordisk's annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. The partnership will
[4]
Novo Nordisk partners with OpenAI to speed drug discovery
Novo Nordisk announced a strategic partnership with OpenAI on Tuesday to apply artificial intelligence across its business, from drug discovery to manufacturing and commercial operations. According to Novo Nordisk, the arrangement is designed to harness OpenAI's tools for making sense of large,
[5]
Novo Nordisk joins forces with OpenAI to fast-track drug research
Danish pharma company Novo Nordisk has announced a partnership with OpenAI to apply artificial intelligence across its drug development process. Novo Nordisk's partnership with OpenAI will "help the company bring new and better treatment options to patients faster," the Danish pharmaceutical
[6]
OpenAI partners with Novo Nordisk to accelerate drug discovery and delivery - SiliconANGLE
OpenAI partners with Novo Nordisk to accelerate drug discovery and delivery Artificial intelligence powerhouse OpenAI Group PBC is lending its expertise to Novo Nordisk A/S in a new partnership announced today that aims to accelerate research in the pharmaceutical industry. The sweeping
[7]
Novo Nordisk Expands AI Push With ChatGPT Parent OpenAI - Novo Nordisk (NYSE:NVO)
AI To Accelerate Drug Discovery The collaboration will leverage advanced AI tools to analyze complex datasets, identify promising drug candidates, and streamline the transition from early-stage research to clinical application. The initiative is designed to reduce development timelines, a
[8]
Novo Nordisk Teams With OpenAI to Speed Drug Development
Novo Nordisk said on Tuesday it will partner with OpenAI to use artificial intelligence across drug discovery, manufacturing, and commercial operations. The Wegovy and Ozempic maker will start pilot programs across research, development, and business units. It plans full integration by the end of
[9]
Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery -- Update
Novo Nordisk said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in the medical field as healthcare companies seek to harness the technology to get ahead of the competition. The Danish drugmaker said it would
[10]
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial
Share
Copy Link
Novo Nordisk announced a strategic partnership with OpenAI to integrate artificial intelligence across its operations, from drug discovery to manufacturing. The Danish drugmaker aims to analyze complex datasets, identify promising drug candidates faster, and regain competitive ground in the weight-loss drug market against rival Eli Lilly. Full integration is planned by the end of 2026.
Novo Nordisk Forms Strategic Partnership with OpenAI to Transform Drug Development
Novo Nordisk announced a comprehensive partnership with OpenAI on Tuesday to integrate artificial intelligence across its entire business operations, marking a significant shift in how the Danish pharmaceutical giant approaches drug discovery and development
1
2
. The collaboration will enable Novo Nordisk to leverage OpenAI's advanced AI capabilities to analyze complex datasets, identify promising drug candidates earlier in the research process, and accelerate drug development timelines3
. While financial terms were not disclosed, the partnership extends beyond Novo's existing AI initiatives, which include a research-focused deal with Nvidia announced last year1
.
Source: Benzinga
Accelerating Drug Discovery in Response to Market Pressures
The partnership with OpenAI comes as Novo Nordisk works to regain its position in the intensely competitive weight-loss drug market, where it has lost ground to US rival Eli Lilly despite being first to market with the current generation of obesity treatments
1
2
. The maker of Wegovy and Ozempic launched oral Wegovy in January, while Eli Lilly secured US approval for its competing weight-loss pill Foundayo earlier this month2
. Analysts expect annual revenue from new obesity drugs to exceed $100 billion in the next decade, intensifying the race for innovation2
.
Source: Reuters
Enhancing Drug Discovery Through Advanced AI Capabilities
The partnership will enable Novo Nordisk to identify drug targets more quickly and design better clinical trials, while gaining clearer insights from the company's vast datasets, according to CEO Mike Doustdar
1
. "There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives," Doustdar said3
4
. "Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever"5
.
Source: SiliconANGLE
Pilot Programs Across Operations with Full Integration by Year-End
Pilot programs will begin across Novo Nordisk's research and development, manufacturing, and commercial operations units, with full integration planned by the end of 2026
1
2
. The collaboration will apply OpenAI's technology to improve efficiency in manufacturing, supply chain, distribution, and corporate operations2
5
. Novo employees already had access to a bespoke version of ChatGPT, but the new partnership extends significantly beyond that capability1
4
. OpenAI will also help train Novo Nordisk's global workforce to increase AI literacy and boost productivity across departments2
4
.Supercharging Scientists, Not Replacing Them
"The aim here is not replacing our scientists. It's about supercharging them," Doustdar emphasized in an interview, noting that "the same would go for many of our employees"
1
2
. He compared the transformation to the shift from using fax machines to email when he first started at the company1
. The partnership is not intended to cut Novo's current workforce but rather to lift productivity and curb the pace of future hiring, Doustdar explained2
4
. This approach follows Doustdar's restructuring efforts since taking over as CEO in August, which eliminated about 9,000 jobs while pushing for a performance culture of faster decision-making1
.Related Stories
AI in the Pharmaceutical Industry: Promise and Reality
The pharmaceutical industry is increasingly investing in AI for drug discovery and development, with drugmakers pouring billions into the technology. Precedence Research estimates the global drug industry's investment in AI will reach $2.51 billion in 2026
4
. However, industry executives acknowledge that while AI has proven valuable for streamlining tedious tasks such as finding participants for clinical trials, selecting sites, and preparing regulatory filings, the technology has not yet fully delivered on the harder challenge of discovering major new molecules2
4
. Big Pharma has yet to see a market-ready drug developed entirely through AI4
. Eli Lilly announced a partnership with Insilico Medicine in March 2026 worth up to $2.75 billion to develop medicines using artificial intelligence, highlighting the competitive race in AI-powered life sciences innovation5
.Data Protection and Governance Framework
Novo Nordisk emphasized that the partnership includes strict data protection, governance, and human oversight protocols to ensure ethical and compliant use of AI
2
4
. The collaboration builds on Novo's existing AI initiatives with other technology partners and research organizations2
. In 2024, the Novo Nordisk Foundation partnered with Nvidia and Denmark's Export and Investment Fund to establish the Danish Centre for AI Innovation, which operates Gefion, Denmark's first AI-ready supercomputer for healthcare and life sciences research5
. "AI is reshaping industries and in life sciences, it can help people live better, longer lives," said Sam Altman, CEO of OpenAI, who has separately invested more than $100 million of his own money in AI-based drug startups2
4
. Novo Nordisk stock rose 2.8% after the opening bell following the announcement4
.References
Summarized by
Navi
Related Stories
Novo Nordisk Expands Indian Operations, Partners with AI Startups to Enhance Drug Development
11 Oct 2024•Business and Economy
Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development
29 Mar 2026•Business and Economy
Eli Lilly Signs $1.3 Billion AI-Driven Deal with Superluminal for Obesity Drug Discovery
15 Aug 2025•Business and Economy
Recent Highlights
1
OpenAI Claims AI Math Breakthrough on Navier-Stokes, Sparks Controversy Over Credit and Future of Research
Science and Research
2
Nvidia CEO Jensen Huang Declares AGI Has Arrived With OpenAI's GPT-6 Astra Release
Technology
3
Apple debuts $1,999 iPhone Duo foldable and A20 Pro chip as new CEO John Ternus takes the stage
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
